DOACs for Prevention of VTE: A Comprehensive Guide for the Pharmacist

This resource center is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Venous thromboembolism (VTE) events manifest as deep vein thrombosis and pulmonary embolisms. These events can often occur in surgical patients within 6 weeks post discharge. The vitamin K agonist warfarin has historically been used for VTE treatment and prophylaxis, but is associated with numerous challenges such as dosage adjustments due to variable dose response. However, in the past decade direct oral anticoagulants (DOACs) have emerged with a role in VTE treatment and prophylaxis. DOACs have improved dosing and limited interactions, both of which are important considerations for pharmacists involved in transitions of care for patients at high risk for VTE. Pharmacists practicing in the health-system setting have important roles in establishing protocols and promoting the utilization of DOACs for VTE prophylaxis in high-risk patients to prevent serious post-discharge complications and decrease associated financial burden. This VTE Curriculum series will equip pharmacists to identify patients at high risk for VTE through included patient case activities. Pharmacists who complete all activities in the Curriculum will receive a Certificate of Completion, demonstrating their dedication to improving patient outcomes with the use of DOACs in VTE.

CE Activity Curriculum

Track Progress

Additional Video

Additional Resources

Latest news from Pharmacy Times: